The debate mentioned tau PTM targeting but did not identify which modifications are both disease-specific and accessible for therapeutic intervention. This knowledge gap limits the development of PTM-based selective targeting approaches.
Source: Debate session sess_SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd (Analysis: SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd)
Acetylation at Lys-280 within the microtubule-binding repeat domain converts tau into an aggregation-competent state by simultaneously disrupting microtubule binding and creating a β-sheet nucleation interface that templates unmodified tau.
No AI visual card yet
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
6 citations6 with PMID5 mediumValidation: 42%5 supporting / 1 opposing
✓For(5)
5
No opposing evidence
(1)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
3
1
2
MECH 3CLIN 1GENE 2EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Reducing acetylated tau is neuroprotective in brai…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-12 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Mechanistically-Specific Hypotheses: Disease-Specific and Therapeutically-Accessible Tau PTMs
Title: K280 acetylation defines pathogenic tau conformers
Mechanism: p300/CBP-mediated acetylation at K280 (within the microtubule-binding repeat domain) converts tau into a aggregation-competent state by disrupting microtubule binding while simultaneously creating a β-sheet nucleation interface. This acetylated form recruits unmodified tau into oligomers, functioning as a dominant-
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Skeptic's Evaluation of Mechanistically-Specific Tau PTM Hypotheses
Hypothesis 1: K280 Acetylation as Aggregation Nucleation Site
Strongest Specific Weakness
Mechanistic claim exceeds structural evidence. The assertion that K280 acetylation creates a "β-sheet nucleation interface" implies a defined conformational change, yet no atomic-resolution structure of acetylated tau exists showing how this modification templated aggregation. The proposed mechanism conflates correlation (K280 acetylation correlates with disease) with causation (acetylation drives nucleation). W
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Domain Expert Assessment: Tau PTM Translational Potential
1. Prioritized Hypotheses by Translational Potential
Hypothesis A (Highest Priority): Truncation at Asp-421 as a Disease-Specific, Amplifiable Seed
Why this rises to top translational candidate:
| Dimension | Assessment | |-----------|------------| | Disease Specificity | C-terminal truncation at D421 is detected in human AD brain but not age-matched controls with normal cognition (Zhao et al., 2016; PMID: 26797856). Unlike phosphorylation (ubiquitous in aging), this cleavage event appears restricted to patho
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{ "ranked_hypotheses": [ { "rank": 1, "title": "Caspase-2/3-mediated D421 truncation generates disease-specific aggregation seeds", "mechanism": "Proteolytic cleavage at Asp-421 by caspase-2/3 produces aggregation-competent tau C-terminal fragments that are detected in human AD brain but absent in age-matched cognitively normal controls.", "target_gene": "CASP2/CASP3", "confidence_score": 0.75, "novelty_score": 0.55, "feasibility_score": 0.65, "impact_score": 0.85, "composite_score": 0.73, "testable_prediction": "Caspase-2 kno
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF pre-formed fibrils composed of K280-acetylated tau (ac-Tau, at 1:10 seed:substrate ratio) are added to solutions of unmodified full-length 2N4R wild-type tau (25 μM), THEN wild-type tau aggregation will reach 50% ThT fluorescence by ≤48 hours versus ≥96 hours for untreated or non-acetyl seed controls.
pendingconf: 0.82
Expected outcome: Accelerated ThT-positive aggregation kinetics of unmodified tau seeded by K280-acetylated tau
Falsified by: K280-acetylated tau seeds fail to accelerate wild-type tau aggregation (ThT curves superimposable with non-seeded or non-acetyl-seeded controls), disproving the nucleation interface hypothesis.
Method: In vitro aggregation assay with recombinant human 2N4R tau expressed in E. coli (Corning 3882 clear-bottom 96-well plates, 300 rpm shaking at 37°C), ThT fluorescence (excitation 440 nm, emission 480 nm) monitored every 2 hours. K280 acetylation verified by mass spectrometry and confirmed with anti-acetyl-lysine antibody. Seed prepared by sonication to 5-10 μm length.
IF primary neurons from tau transgenic mice are treated with the p300/CBP inhibitor A-485 (1 μM for 7 days) or express a K280R non-acetylatable tau mutant, THEN phospho-tau solubility will increase by ≥40% and Sarkosyl-insoluble tau aggregates will decrease by ≥60% compared to vehicle-treated or wild-type tau-expressing neurons.
pendingconf: 0.75
Expected outcome: Reduced accumulation of Sarkosyl-insoluble, aggregated tau in neurons
Falsified by: No significant difference in tau aggregation between p300-inhibited/K280R mutant neurons and controls (i.e., <20% change in insoluble tau), indicating K280 acetylation is not required for aggregation.
Method: Primary cortical neurons from 3xTg or P301S tau mice cultured for 14 days in vitro, treated with A-485 or transduced with AAV-K280R, followed by sequential extraction (TBS, Triton, Sarkosyl) and immunoblot for total tau (Tau5) and pS396 (AT8). N≥3 biological replicates per condition.